AKT1 and Splenomegaly: No differences in signaling capacity of AKT, mTOR and S6 were observed between patients with autoimmune manifestations, autoimmune cytopenia, lymphoproliferation, granuloma formation or splenomegaly (Supplementary Figure S4B), indicating that none of the complications can be directly associated with a particular signaling profile within the group of CVID patients.